FORMELA JEAN FRANCOIS sold $686K of KRRO (indirect holdings)

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 • Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background • Administered a single dose of 2mg/kg to the

Korro Bio (KRRO) has dosed the first cohort in its Phase 1/2 trial for KRRO-121, an RNA-editing treatment for hyperammonemia. The trial, conducted in Australia, includes healthy volunteers and plans to dose Urea Cycle Disorder patients in early 2027, with interim results expected later that year.

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan

L1 Capital Pty Ltd purchased 272,695 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $7.18 ($1.96M total) on 2026-10-06.

Troim Tor Olav purchased 1,250,000 indirectly-held shares of Borr Drilling Ltd (BORR) at $4.31 ($5.39M total) on 2026-10-07.